ProCE Banner Activity

Low-Dose Hypomethylating Agents Effective, Safe in Low/Int-1 Risk MDS

Slideset Download
Conference Coverage
Overall response rate 59% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen